BioCentury

8:00 AM GMT, Feb 21, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Status

Nimotuzumab: Completed Phase II enrollment

YM BioSciences disclosed in its fiscal 2Q11 earnings that partner Daiichi Sankyo completed enrollment in a Phase II trial evaluating nimotuzumab in combination with radiation therapy,

Read the full 268 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.